Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain

NCT00736151 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.

NCT NCT00736151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00736151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Pilot, Randomised, Double Blind Placebo Controlled Dose Titration Study to Evaluate the Safety, Maximum Tolerated Dose and Preliminary Evidence of Efficacy of Orally Administered Ralfinamide at Four Doses (80, 160, 240 and 320 mg/Day) in Patients With Neuropathic Pain
Lead sponsor
Newron Pharmaceuticals SPA
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
Not reported
Enrollment
272 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic pain